{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:50:54Z","timestamp":1793040654842,"version":"4.5.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T00:00:00Z","timestamp":1550016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007232","name":"Radiumhemmets Forskningsfonder","doi-asserted-by":"publisher","award":["Ref 161023"],"award-info":[{"award-number":["Ref 161023"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN20166\/307"],"award-info":[{"award-number":["CAN20166\/307"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0211927","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T19:11:52Z","timestamp":1550085112000},"page":"e0211927","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":107,"title":["Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma"],"prefix":"10.1371","volume":"14","author":[{"given":"Hareth","family":"Nahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chrobok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6069-6615","authenticated-orcid":true,"given":"Charlotte","family":"Gran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6sta","family":"Gahrton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0339-8259","authenticated-orcid":true,"given":"Arnika Kathleen","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evren","family":"Alici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,2,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"34310","DOI":"10.1038\/srep34310","article-title":"CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes","volume":"6","author":"WH Yeap","year":"2016","journal-title":"Sci Rep"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma","volume":"373","author":"HM Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"MA Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"MV Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"A Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"T Casneuf","year":"2017","journal-title":"Blood Adv"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bjh.13776","article-title":"Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach","volume":"174","author":"E Alici","year":"2016","journal-title":"Br J Haematol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"S Lonial","year":"2016","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"SZ Usmani","year":"2016","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"C Blimark","year":"2015","journal-title":"Haematologica"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1046\/j.1365-2141.2001.02871.x","article-title":"Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion","volume":"113","author":"S Mariani","year":"2001","journal-title":"British Journal of Haematology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","article-title":"Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis","volume":"67","author":"BW Teh","year":"2016","journal-title":"Eur J Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2005-08-3494","article-title":"Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation","volume":"108","author":"A Nencioni","year":"2006","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/tid.12162","article-title":"High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network","volume":"16","author":"F Marchesi","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/ejh.12551","article-title":"Cytomegalovirus reactivation in patients with multiple myeloma","volume":"96","author":"T Hasegawa","year":"2016","journal-title":"Eur J Haematol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"S Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"SV Rajkumar","year":"2011","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"AS Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"ref19","first-page":"S1","article-title":"K\/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"ref20","first-page":"81","article-title":"The Revival of an "Old" Marker: CD4\/CD8 Ratio","volume":"19","author":"G Bruno","year":"2017","journal-title":"AIDS Rev"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"M de Weers","year":"2011","journal-title":"J Immunol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S1286-4579(02)00038-2","article-title":"Human natural killer cell deficiencies and susceptibility to infection","volume":"4","author":"JS Orange","year":"2002","journal-title":"Microbes Infect"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1158\/1078-0432.CCR-17-3117","article-title":"Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo-Expanded Autologous NK Cells","volume":"24","author":"YF Wang","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"ref24","article-title":"CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes","volume":"6","author":"WH Yeap","year":"2016","journal-title":"Scientific Reports"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"10820","DOI":"10.1128\/JVI.00365-08","article-title":"Natural killer cells as novel helpers in anti-herpes simplex virus immune response","volume":"82","author":"S Nandakumar","year":"2008","journal-title":"J Virol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1099\/0022-1317-66-5-1087","article-title":"Injection of Anti-thy-1.2 Serum Breaks Genetic Resistance of Mice against Herpes Simplex Virus","volume":"66","author":"W Chmielarczyk","year":"1985","journal-title":"Journal of General Virology"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3389\/fimmu.2018.00183","article-title":"Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells","volume":"9","author":"HS Dai","year":"2018","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3390\/v1030979","article-title":"Innate and adaptive immune responses to herpes simplex virus","volume":"1","author":"T Chew","year":"2009","journal-title":"Viruses"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"E7128","DOI":"10.1073\/pnas.1521651112","article-title":"Severe infectious diseases of childhood as monogenic inborn errors of immunity","volume":"112","author":"JL Casanova","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12979-017-0093-4","article-title":"Herpes virus seroepidemiology in the adult Swedish population","volume":"14","author":"J Olsson","year":"2017","journal-title":"Immun Ageing"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e16103","DOI":"10.1371\/journal.pone.0016103","article-title":"Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States","volume":"6","author":"AM Simanek","year":"2011","journal-title":"PLoS One"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1532-5415.2005.53250.x","article-title":"Chronic cytomegalovirus infection and inflammation are associated with prevalent frailty in community-dwelling older women","volume":"53","author":"HN Schmaltz","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"P Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"ref34","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1038\/bmt.2008.120","article-title":"CMV infections after hematopoietic stem cell transplantation","volume":"42","author":"P Ljungman","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"J Krejcik","year":"2016","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"e0193299","DOI":"10.1371\/journal.pone.0193299","article-title":"Reduced NK cell IFN-gamma secretion and psychological stress are independently associated with herpes zoster","volume":"13","author":"CK Kim","year":"2018","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e27664","DOI":"10.1371\/journal.pone.0027664","article-title":"Characterization of natural killer cell phenotype and function during recurrent human HSV-2 infection","volume":"6","author":"NK Bjorkstrom","year":"2011","journal-title":"PLoS One"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/bs.ai.2016.10.001","article-title":"About Training and Memory: NK-Cell Adaptation to Viral Infections","volume":"133","author":"Q Hammer","year":"2017","journal-title":"Adv Immunol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jpeds.2004.11.022","article-title":"Fatal varicella associated with selective natural killer cell deficiency","volume":"146","author":"A Etzioni","year":"2005","journal-title":"J Pediatr"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2004-05-2058","article-title":"Imprint of human cytomegalovirus infection on the NK cell receptor repertoire","volume":"104","author":"M Guma","year":"2004","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/cei.12785","article-title":"Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans","volume":"185","author":"AB Bigley","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood-2016-07-726729","article-title":"Phase 1\/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"128","author":"T Plesner","year":"2016","journal-title":"Blood"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0211927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T18:21:16Z","timestamp":1606501276000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0211927"}},"subtitle":[],"editor":[{"given":"Alan","family":"Landay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0211927","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,13]]}}}